EverPoint Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$21M Sell
1,300,000
-375,000
-22% -$6.8M 0.39% 62
2016
Q3
$30.4M Sell
1,675,000
-125,000
-7% -$2.44M 0.55% 41
2016
Q2
$29.6M Buy
1,800,000
+500,000
+38% +$8.09M 0.58% 38
2016
Q1
$21.5M Buy
1,300,000
+1,150,000
+767% +$20.1M 0.42% 48
2015
Q4
$3.25M Sell
150,000
-325,100
-68% -$6.33M 0.07% 325
2015
Q3
$9.42M Buy
475,100
+225,100
+90% +$7.11M 0.24% 121
2015
Q2
$8.69M Sell
250,000
-175,000
-41% -$5.34M 0.16% 194
2015
Q1
$11M Sell
425,000
-275,000
-39% -$5.04M 0.21% 152
2014
Q4
$9.02M Buy
700,000
+395,400
+130% +$4.95M 0.2% 167
2014
Q3
$3.74M Buy
+304,600
New +$3.54M 0.09% 290

Other funds holding HZNP

EverPoint Asset Management's HZNP Position: Q4 2016 in Review

EverPoint Asset Management reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 22% in Q4 2016, selling an estimated $6.8M and leaving 1,300,000 shares worth $21M. The position accounts for 0.39% of the portfolio, ranked #62.

EverPoint Asset Management first reported a position in HZNP in Q3 2014 and has held it in 10 quarters since. The position peaked at $30.4M in Q3 2016. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

  • EverPoint Asset Management held 1,300,000 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $21M as of Q4 2016.
  • EverPoint Asset Management sold 375,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $6.8M.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.39% of EverPoint Asset Management's portfolio in Q4 2016, its #62 holding.
  • EverPoint Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2014 and has held it in 10 quarters since.
  • EverPoint Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $30.4M in Q3 2016.
  • 234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.